This symposium will include presentations on high-dose GLP-1 RAs in treatment of type 2 diabetes, a look at the role of GLP-1 co-agonists, the availability of high-dose semaglutide for treatment of obesity, and the potential of GLP-1 RAs in cardiometabolic care. The session begins at 2:15 p.m. CT on Monday in Great Hall A at the convention center. A livestream and on-demand recording are available at ADA2022.org.